SOURCE: Brower Piven, A Professional Corporation

December 03, 2010 15:55 ET

Brower Piven Encourages Investors Who Have Losses in Excess of $200,000 From Investment in MELA Sciences, Inc. to Inquire About the Lead Plaintiff Position in Securities Fraud Class Action Lawsuit Before the January 21, 2011 Lead Plaintiff Deadline

STEVENSON, MD--(Marketwire - December 3, 2010) - Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of the common stock of MELA Sciences, Inc. ("MELA" or the "Company") (NASDAQ: MELA) during the period between February 13, 2009 and November 16, 2010, inclusive (the "Class Period").

No class has yet been certified in the above action. Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than January 21, 2011 and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period. You are not required to have sold your shares to seek damages or to serve as a Lead Plaintiff.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the Company's failure during the Class Period, to be forthcoming regarding the status of MelaFind's ongoing clinical studies and the safety and efficacy of MelaFind.

According to the complaint, on November 16, 2010, it was reported that MelaFind "could cause harm because of the potential for misdiagnosis" and that FDA staff had identified numerous problems with Mela's study of the MelaFind device, including a significant lack of data, and urged a new clinical trial, the value of MELA stock declined significantly.

If you have suffered a net loss for all transactions in MELA Sciences, Inc. common stock during the Class Period, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 50 years. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.

Contact Information

  • CONTACT:
    Charles J. Piven
    Brower Piven, A Professional Corporation
    Stevenson, Maryland
    410/415-6616
    Email Contact